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Papillary thyroid carcinoma (PTC) is the most predominant subtype of thyroid cancer, contributing to more 
than 80% of all thyroid or endocrine malignancies. However, the role of Long noncoding RNA long stress induced 
non-coding transcripts (LSINCT5) in papillary thyroid cancer remains largely unknown. In the present study, 
we found that the expression of LSINCT5 in PTC cell line was higher than that in human normal thyroid cell 
HT-ori3. The proliferation and migration ability of PTC cell lines TPC-1 and KAT-5 cells were significantly 
decreased after transfection of siLSINCT5-1 and siLSINCT5-2 compared with siNC transfection. The dual 
luciferase reporter gene and RIP confirmed that LSINCT5 is capable of specifically binding to miR-29c. 
Compared with the transfected LSINCT5 group, the proliferation and migration ability of TPC-1 cells in the co-
transfected LSINCT5 and miR-29c groups were significantly decreased, and the expression of ITGB1 mRNA 
and protein were down-regulated either. Taken together, our data indicated that LSINCT5 can inhibit the tumor 
suppressive effect of miR-29c-ITGB1 axis and promote the proliferation and metastasis of PTC by targeting 
miR-29c-ITGB1 axis. 
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Papillary thyroid carcinoma (PTC) is the most predominant 
subtype of thyroid cancer, contributing to more than 80% of 
all thyroid or endocrine malignancies. Its prognosis is 
relatively good compared to other cancers, with more than 90% 
overall 10-year survival rate [1]. Treating recurrent PTCs is 
still a challenge and one of the important issues yet to be 
solved in PTC patient management is the mortality and 
morbidity associated with the recurrent disease. Therefore, in-
depth study of the mechanism of PTC development from the 
molecular level has important clinical significance and value 
for the diagnosis and treatment of PTC. 
Genetic and epigenetic changes are associated with the 
initiation and progression of a variety of cancers, including 
PTC. The regulation of long noncoding RNAs (lncRNAs) is 
an important type of epigenetic regulation. Recent studies 
have shown that a variety of lncRNAs are transcriptionally 
dysregulated in cancer, playing a role in promoting cancer or 
suppressing cancer [2-3]. For example, lncRNAs BANCR, 
MEG3, and PTCSC3 are transcriptionally down-regulated in 
PTC to function as tumor suppressors [4-6]. The lncRNAs 
ANRIL, HOTAIR and MALAT1 are up-regulated in PTC to 
play a role in cancer promotion [7-8]. However, the 
mechanism of action of a large number of lncRNAs in PTC is 
not clear. By reviewing of the evidence, the critical role of 
long noncoding RNA (lncRNA) LSINCT5 in a large number 
of human cancers is indicated. However, the mechanistic 
involvement of LSINCT5 in PTC is still unknown.  
MicroRNAs (miRNAs) are short, endogenous noncoding 
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RNAs first identified in Caenorhabditis elegans which 
regulate gene expression by binding to the 3′-UTR of target 
messenger RNA (mRNAs). Their post-transcriptional 
regulatory functions are involved in controlling the level of 
proteins involved in numerous biological processes, including 
embryogenesis, organogenesis, tissue homeostasis, immune 
system function and cell cycle control [1]. Relationship 
between miRNAs and tumor growth, tumor progression and 
metastasis has been demonstrated by many studies, indicating 
the ability of these molecules to be used as biomarkers for 
diagnosis and prognosis [9]. miRNA also plays a role as 
biomarker in predicting lymph nodes metastasis (LNM) in 
thyroid cancer [10]. 
This study shows that knockdown of LSCINC5 expression 
significantly inhibited the proliferation and metastasis of PTC 
cell lines TPC-1 and KAT-5. Dual luciferase reporter assay 
confirms that LSENC5 can compete for competitive binding 
to miR-29c. Co-transfection experiments further revealed that 
miR-29c can inhibit the proliferation and metastasis of PTC 
by LSINCT5 after overexpression of LSINCT5. qRT-PCR 
and Western blot analysis showed that miR-29c can reverse 
the up-regulation of ITGB1 expression by LSINCT5 after 
overexpression of LSINCT5, in addition to promote the 
expression of E-cadherin. These results indicate that 
LSINCT5 can function as a molecular sponge of miRNAs, 
inhibits the tumor suppressor of miR-29c-ITGB1 axis, and 
promotes proliferation and metastasis of PTC. 
Materials and methods 
Cell culture 
The human normal thyroid cell line HT-ori3 and the PTC 
cell lines NPA87, KAT-5, and TPC-1 were cultured in DMEM 
(HyClone) medium containing 10% fetal bovine serum 
(HyClone). The incubator culture temperature was set to 37 °C 
and the CO2 content was 5%. 
qRT-PCR detection of relative expression of lncRNA LSINCT5 
and ITGB1 
Total RNA in tissue and cell samples was extracted using 
the Trizol method and total RNA was reverse transcribed into 
cDNA using random primers. The upstream primers and 
downstream primers corresponding to the premix, cDNA 
template, lncRNA LSINCT5 and ITGB1 were added 
according to the qRT-PCR quantitative detection kit (TaKaRa) 
step. lncRNA LSINCT5 upstream: 5'-TAGTGGACAGAG-
CCTACCCC-3', lncRNA LSINCT5 downstream: 5'-CCAGC-
TACCACCCACAACAA-3'; ITGB1 upstream: 5'-AGTAGT-
GCACTTTTCTCTCATGG-3', ITGB1 downstream: 5'-CCC-
GTCCACCCATTTCTACC-3'; internal reference GAPDH 
upstream: 5'-TGGCTATTGCCGAATCGCTG-3', down-
stream of GAPDH: 5'-CCTAGGCTTGAATCGGTCT-3'; 
reaction conditions: 95 °C for 3 min; 40 cycles of denaturation 
at 95 °C for 15 s; annealing at 60 °C for 20 s; 72 °C for 20 s, 
each One cycle collected fluorescence at 72 °C. qRT-PCR 
results were quantitatively analyzed using the 2-ΔΔCt method. 
Detection of proliferation ability of PTC cells transfected with 
TPC-1 and KAT-5 by CCK-8 assay 
The PTC cells TPC-1 and KAT-5 were prepared as single 
cell suspensions, adjusted to a cell concentration of 2 × 104/mL, 
and seeded into 96-well plates at a volume of 100 μL per well. 
After TPC-1 and KAT-5 cells were attached, siNC, 
siLSINCT5-1, siLSINCT5-2, Control (empty plasmid group), 
LSINCT5, LSINCT5-Mut, LSINCT5 and miR-29c were 
transfected, respectively. At 24, 48, and 72 h after transfection, 
10 μL of CCK-8 reagent was added to each well and mixed. 
After continuing to incubate for 1 h at 37 °C, 5% CO2, the 
optical density value D (450) at 450 nm of each well was 
measured using a Bio-Rad iMark microplate reader (the blank 
control value was automatically subtracted when the 
instrument automatically reads).  
QCMTM Laminin Migration Transfer Kit for the migration of 
TPC-1 and KAT-5 after transfection 
The QCMTM Laminin Migration Kit (Millipore, Germany) 
was removed from the 4 °C freezer and allowed to equilibrate 
for 1 h at room temperature. 0.5 mL of complete medium was 
added to a 12-well plate in the lower chamber of Transwell, 
and 200 μL of the single cell suspension that had been 
prepared was added to the Transwell chamber. After co-
cultivation for 24 h, the upper layer of Transwell chamber was 
wiped off with a cotton swab and fixed in 95% ethanol for 20 
min. It was placed in a clean bench and dried, then stained with 
0.1% crystal violet for 15 min. Wash into the PBS solution 
several times. After drying again, 3 to 5 fields of view were 
taken on the diameter of the Transwell chamber, and the 
number of transmembrane cells was counted after 
photographing under a microscope. 
LSINCT5-Wt and LSINCT5-Mut fluorescent reporter vector 
construction and luciferase activity assay 
The LSINCT5-Wt sequence fragment was amplified by 
PCR and the LSINCT5-Mut sequence was obtained using the 
Promega site-directed mutagenesis kit (Promega, Shanghai). 
The luciferase reporter vector pmir-GLO was inserted after 
double digestion. miR-29c and the negative control miR-NC 
were co-transfected into HEK293 cells with the successfully 
constructed LSINCT5-Wt and LSINCT5-Mut reporter plas-
mids. After 24 h of transfection, the corresponding fluore-
scence intensity was measured and the relative activity of 
luciferase was calculated. 
Western blotting 
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Figure 1. Knockdown of LSINCT5 expression inhibits proliferation and metastasis of PTC cell lines TPC-1 and KAT-5. A, B: qRT-
PCR detects the expression level of LSIPT5 in TPC-1 and KAT-5 after transfection of siLSINCT5 (n= 3,x±s); C, D: CCK-8 detects the 
proliferation of TPC-1 and KAT-5 after transfection of siLSINCT5; E, F: Transwell migration assay detects the change of TPC-1 transfer 
ability after transfection of siLSINCT5 ( n=5, x±s); G, H: Transwell migration assay detected changes in KAT-5 metastasis after 
transfection of siLSINCT5 (n=5, x±s); a: P < 0.05, compared with siNC group. 
 
The TPC-1 cells after lysis with RIPA lysis buffer were 
centrifuged at 12 000 × g for 15 min, and the supernatant was 
collected and the protein concentration was determined. 
Protein loading buffer (5 × SDS) was added in a ratio of 4:1 
and boiled in a metal bath for further use. The appropriate 
amount of the sample was separated by 12% SDS-PAGE gel, 
wet transferred onto a PVDF membrane, and blocked with 3% 
skim milk powder, respectively, using mouse-derived anti-
ITGB1 primary antibody (Abcam, USA) (1:1 000 dilution), 
mouse-derived anti-E-cadherin primary antibody (Abcam, 
USA) (1:800 dilution), mouse-derived anti-GAPDH primary 
antibody (Abcam, USA) (1:2) Incubate for 1000 overnight, 
and then incubate with HRP-labeled goat anti-mouse IgG for 
1 h. The PVDF membrane after washing the membrane was 
placed in a dark room exposure imaging apparatus, and a 
chemiluminescent chromogenic substrate was added to detect 
the chemiluminescence of the target protein band.  
Statistics 
Data processing was performed using statistical software 
SPSS 22.0. Measurement data were expressed as x±s, and 
differential analysis was performed using t test. 
Results 
Knockdown of LSINCT5 expression inhibits proliferation and 
metastasis of PTC cell lines TPC-1 and KAT-5 
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The expression level of LSENCT5 in TPC-1 and KAT-5 
cells after transfection of siLSINCT5 was first examined. The 
results showed that the expression levels of LSINCT5 in TPC-
1 and KAT-5 cells were significantly decreased after 
transfection of siLSINCT5-1 and siLSINCT5-2 (P < 0.05, Fig. 
1 A and B). To evaluate the effect of LSINCT5 on the 
proliferation of TPC-1 and KAT-5 cells, CCK-8 assay was 
used to detect the proliferation of cells in each group, as shown 
in Figure 2C and D. Compared with the siNC group, 
siLSINCT5-1, and siLSINCT5-2 group significantly inhibited 
the proliferation of TPC-1 and KAT-5 cells at 72 h after 
transfection (P < 0.05). As shown in Fig. 1E~H, Transwell 
migration experiments showed that the invasive ability of 
TPC-1 and KAT-5 was significantly inhibited in the 
siLSINCT5-1 and siLSINCT5-2 groups compared with the 
siNC group (P < 0.05). 
lncRNA LSINCT5 targeting and binding to miR-29c 
To confirm whether LSISCT5 binds to miR-29c, a dual 
luciferase reporter assay was performed. As a result, as shown 
in Fig. 2, the relative luciferase activity values of the co-
transfected miR-NC and pmirGLO groups were not 
significantly different from the relative luciferase activity 
values of the co-transfected miR-29c and pmirGLO groups. 
The relative luciferase activity values of the co-transfected 
miR-NC and LSINCT5-Mut groups were not significantly 
different from the relative luciferase activity values of the co-
transfected miR-29c and LSINCT5-Mut groups. The relative 
luciferase activity values of the co-transfected miR-NC and 
LSINCT5 groups were significantly lower than those of the 
co-transfected miR-29c and LSINCT5 groups, and the total 
transfection of miR-29c and LSINCT5 groups was 
significantly lower (P < 0.05). The above results indicate that 
LSINCT5 contains a binding site of miR-29c and is capable of 
targeting and binding to miR-29c. This result suggests that 
LSINCT5 may participate in the occurrence and progression 
of PTC by exerting molecular sponge adsorption function and 
binding to miR-29c to play a post-transcriptional regulation. 
 
Figure 2. Dual luciferase reporter assay for LSINCT5 binding to miR-






Figure 3. Co-transfection of miR-29c inhibits the effect of 
LSINCT5 on PTC pro-proliferation and metastasis (n=5, x±s). 
A: Co-transfection of miR-29c inhibits LS-promoting effect of 
LSINCT5; B: co-transfection miR-29c inhibited LSINCT5 on 
PTC-induced metastasis. *P < 0.05, compared with Control 
group; **P < 0.05, compared with the LSINCT5 group. 
 
Co-transfection of miR-29c inhibits the proliferation of PTC 
by LSINCT5 
The results of the proliferation assay are shown in Figure 
3A: compared with the Control (empty plasmid) group, the 
cell proliferation ability of the LSINCT5 group was 
significantly increased 72 h after transfection (P < 0.05); 
compared with the LSINCT5 group, the proliferation of TPC-
1 cells of the LSISTIN5+miR-29c group was significantly 
decreased at 72 h after transfection (P < 0.05). Compared with 
the Control group (Fig. 3), the cell migration ability of the 
LSINCT5 group was significantly increased 72 h after 
transfection (P < 0.05); compared with the LSINCT5 group, 
the LSCINC5+miR-29c group of TPC-1 cells Cell migration 
ability decreased significantly at 72 h after transfection (P < 
0.05). Those results further suggests the binding of LSINCT5 
to miR-29c, while overexpression of miR-29c antagonizes the 
role of LSINCT5 in promoting PTC proliferation and 
metastasis after binding to endogenous miR-29c. 
Co-transfection of miR-29c inhibits the upregulation of ITGB1 
by LSINCT5 
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Figure 4. Co-transfection of miR-29c inhibits the upregulation 
of ITGB1 by LSINCT5. A: qRT-PCR detects the expression 
level of ITGB1 in each group after transfection (n=3, x±s); B: 
Western blot detection The expression of ITGB1 and E-
cadherin in the cells after staining. *P < 0.05, compared with 
Control group; **P < 0.05, compared with the LSINCT5 
group. 
 
Compared with the Control group (Fig. 4A), the expression 
level of ITGB1 was significantly increased at 72 h after 
transfection in the LSINCT5 group (P < 0.05); compared with 
the LSINCT5 group, the expression level of ITGB1 in the 
TPCTIN5+miR-29c group was significantly decreased at 72 h 
after transfection (P < 0.05). The expression level of ITGB1 
protein is consistent with the qRT-PCR results (Fig. 4B). At 
the same time, compared with the Control group, the 
expression level of E-cadherin was decreased at 72 h after 
transfection in the LSINCT5 group. Compared with the 
LSINCT5 group, the expression level of E-cadherin in the 
LSCINC5+miR-29c group at 72 h after transfection is up-
regulated. These results indicate that co-transfection of miR-
29c can reverse the up-regulation of ITGB1 expression by 
LSINCT5 and promote the expression of E-cadherin after 
overexpression of LSINCT5. Moreover, the result suggests 
that LSINCT5 inhibits the anti-cancer effect of miR-29c-
ITGB1 axis by targeting and binding to miR-29c, and further 
promotes the proliferation and metastasis of PTC. 
Discussion 
Papillary thyroid carcinoma is the most predominant 
subtype of thyroid cancer, contributing to more than 80% of 
all thyroid or endocrine malignancies. Its prognosis is 
relatively good compared to other cancers, with more than 90% 
overall 10-year survival rate [1]. However, despite the 
favorable prognosis, some cases exhibit aggressive phenotype. 
On average, 50% of the patients are presented with lymph 
node metastases (LNM) at diagnosis [11]. LNM in PTC 
confers various poor prognostic indicators; it increases 
recurrence risk and decreases long term survival 
predominantly in patients older than 45 years old [12, 13]. 
Treating recurrent PTCs is still a challenge [14] and one of the 
important issues yet to be solved in PTC patient management 
is the mortality and morbidity associated with the recurrent 
disease [15]. 
MicroRNAs (miRNA) are small non-coding RNAs of 
approximately 19-25 nucleotides in length that are responsible 
for the posttranscriptional regulation of gene expression in 
both eukaryotic and prokaryotic cells. Over the past decade, 
many studies have shown that miRNA dysregulation plays an 
important role in cancer development through the regulation 
of essential roles in tumor cell differentiation, migration, 
apoptosis and proliferation [16-22]. These regulatory 
processes are controlled through the over and under 
expression of specific miRNAs, leading to amplified 
expression of oncogenic and tumour suppressing genes. The 
unique miRNA profiles have shown potential in the 
development of cancer biomarkers and novel drugs. The 
alterations in miRNA also translated to the clinical and 
pathological impacts of patients with cancer.  
Recent studies have shown that epigenetic regulation is one 
of the most important regulatory approaches in the body. 
lncRNAs can participate in epigenetic regulation of the body 
through chromatin remodeling, transcriptional regulation, and 
post-transcriptional. It is involved in cell differentiation, 
proliferation, apoptosis, neurodevelopment, immune homeo-
stasis, tumorigenesis and other life processes. 
This study shows that knockdown of LSCINC5 expression 
significantly inhibited the proliferation and metastasis of PTC 
cell lines TPC-1 and KAT-5. Dual luciferase reporter assay 
confirms that LSENC5 can compete for competitive binding 
to miR-29c. Co-transfection experiments further revealed that 
miR-29c can inhibit the proliferation and metastasis of PTC 
by LSINCT5 after overexpression of LSINCT5. qRT-PCR 
and Western blot analysis showed that miR-29c can reverse 
the up-regulation of ITGB1 expression by LSINCT5 after 
overexpression of LSINCT5, in addition to promote the 
expression of E-cadherin. These results indicate that 
LSINCT5 can function as a molecular sponge of miRNAs, 
inhibits the tumor suppressor of miR-29c-ITGB1 axis, and 
promotes proliferation and metastasis of PTC. 
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